To confirm that WB-308 operates via the same mechanism as Gefitinib in response to EGFR mutations, we employed a de novo system to test WB-308′s working model in wild type NSCLC cell line H1299 in order to exclude artificial results and background. This evidence concerns the gene EGFR and non-small cell lung carcinoma.